Tabula Rasa HealthCare Inc (NASDAQ:TRHC) Director Gordon Tunstall sold 15,000 shares of the firm’s stock in a transaction that occurred on Friday, December 8th. The stock was sold at an average price of $25.85, for a total transaction of $387,750.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Tabula Rasa HealthCare Inc (NASDAQ TRHC) traded down $0.01 during midday trading on Monday, reaching $28.59. The company’s stock had a trading volume of 153,525 shares, compared to its average volume of 105,992. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.73 and a quick ratio of 0.66. Tabula Rasa HealthCare Inc has a 52 week low of $11.59 and a 52 week high of $36.80.
Tabula Rasa HealthCare (NASDAQ:TRHC) last announced its quarterly earnings data on Monday, November 6th. The company reported $0.08 EPS for the quarter, topping the Zacks’ consensus estimate of $0.06 by $0.02. Tabula Rasa HealthCare had a negative return on equity of 5.58% and a negative net margin of 2.27%. The business had revenue of $33.27 million during the quarter, compared to the consensus estimate of $31.76 million. During the same period in the previous year, the company posted $0.06 earnings per share. The business’s revenue for the quarter was up 37.6% on a year-over-year basis. sell-side analysts forecast that Tabula Rasa HealthCare Inc will post 0.05 earnings per share for the current fiscal year.
TRHC has been the subject of a number of recent research reports. Piper Jaffray Companies reissued a “buy” rating and set a $29.00 price target on shares of Tabula Rasa HealthCare in a research report on Tuesday, October 24th. UBS raised their price target on shares of Tabula Rasa HealthCare from $18.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, August 30th. BidaskClub cut shares of Tabula Rasa HealthCare from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 6th. Zacks Investment Research cut shares of Tabula Rasa HealthCare from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 10th. Finally, ValuEngine raised shares of Tabula Rasa HealthCare from a “sell” rating to a “hold” rating in a research note on Saturday, September 30th. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $28.25.
Tabula Rasa HealthCare Company Profile
Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.
Receive News & Ratings for Tabula Rasa HealthCare Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare Inc and related companies with MarketBeat.com's FREE daily email newsletter.